CPHI · China Pharma Holdings, Inc. · Executive Compensation
$0.71
0.00 (-0.14%)
At close · Sep 18
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, the Company had cash and cash equivalents of $0.3 million and an accumulated deficit of $49.8 million, and the Company's current liabilities exceeded current assets by $5.7 million. In addition, the Company incurred net losses of $2.6 million and had cash outflows from operating activities of $0.08 million for the six months ended June 30, 2026.”View the 10-Q filed Aug 14, 2026
Market Cap
$31.13M
Shares
43.02M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Zhilin Li | Chairman, Chief Executive Officer President and interim Chief Financial Officer | $241,600 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Zhilin Li | Chairman, Chief Executive Officer President and interim Chief Financial Officer | $241,600 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Zhilin Li | Chairman, Chief Executive Officer President and interim Chief Financial Officer | $241,600 |
Key facts
CIK
1106644
CUSIP
16941T401
13F (30d)
1 filings
1 filers